Valeant Pharmaceuticals Intl Inc.: We Are Still in the Early Innings

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is not even close to the end of the tunnel.

The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares have rebounded nicely over the past couple of weeks; as of this writing, they have gained roughly 40%.

Interestingly, there have been few new developments over this time, and that may be precisely why Valeant’s stock price has rebounded. In other words, the lack of headlines may have convinced some investors that Valeant’s troubles will pass.

But don’t be fooled. Valeant is still in the early innings of its saga, and the end result could be devastating. We take a closer look below.

More dirty tricks

If you believe Valeant’s story, then all of its problems can be traced to a rogue specialty pharmacy called Philidor, which accounted for just a small percentage of the drug maker’s sales (before Valeant terminated the relationship).

But old habits die hard, and some believe that Valeant is still using similar tactics. One of them is John Hempton of Bronte Capital, who notes that numerous pharmacies have been sprouting up that all seem to have ties to Valeant. One of these pharmacies recently applied for a license in Arizona, with former Valeant employee Gary Tanner presenting himself as the owner.

Meanwhile, numerous authorities–from attorneys’ offices to politicians–are investigating Valeant for its pricing practices. It’s safe to say that there are still many more headlines to come.

The role of pharmacy benefit managers

Pharmacy benefit managers (PBMs) such as Express Scripts can be thought of as the “gatekeepers” in the pharmaceutical world. Their role is mainly to negotiate drug prices with the pharmaceutical companies and process drug claims.

The power of PBMs cannot be overstated. They were the ones who first decided to stop working with Philidor (which is what prompted Valeant to sever that relationship). They are also making life very difficult for Turing Pharmaceuticals after the company raised the price of Daraprim by over 5,000%.

If PBMs start dropping Valeant drugs from their formularies and replace these drugs with generics, then Valeant’s profits could take a significant hit.

Simply too risky

Let’s not forget, Valeant has roughly US$30 billion in debt, which isn’t all that surprising for a company that’s so acquisitive. But it does mean that any dent in its business model could put pressure on its balance sheet, too. This is not a position any company wants to be in, much less one with as many enemies as Valeant has. You should stay far away from this stock.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

jar with coins and plant
Dividend Stocks

How Much to Invest in TC Energy for $142 a Quarter in Dividends

With predictable cash flows, consistent dividend growth, an attractive yield, and clear growth opportunities, TC Energy is ideal for income-seeking…

Read more »

Digital background depicting innovative technologies in (AI) artificial systems, neural interfaces and internet machine learning technologies
Tech Stocks

Where Could Celestica Stock Be in 5 Years? What the New Outlook Means

Celestica’s ambitious 2027 outlook and accelerating AI infrastructure demand could fuel its next phase of growth, making its recent stock…

Read more »

man in bowtie poses with abacus
Dividend Stocks

How Much Would You Need in SmartCentres to Collect $250 a Month?

SmartCentres can pay an actual monthly distribution. Reaching $250 from it alone would require nearly $45,000 at recent prices.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Stock Market

One ETF or Several? How to Keep Your Investments as Simple as Possible

Here's how choosing the right mix of ETFs could help you simplify your investments while building long-term wealth.

Read more »

ETFs can contain investments such as stocks
Dividend Stocks

1 Top Dividend ETF to Buy to Generate Passive Income

Vanguard's VDY pays monthly with a 0.22% MER and a 3% yield. See what $20,000 could earn, the bank and…

Read more »

groceries get more expensive as inflation rises
Dividend Stocks

2 TSX Giants to Buy for Decades of Growth and Dividends

Royal Bank of Canada (TSX:RY) and another dividend giant worth buying up for decades.

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

2 of the Best ETFs to Buy Now

Looking for the best ETFs to buy now? Explore how XEQT offers global stock exposure while ZAG adds Canadian bonds…

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

A TFSA-Worthy Dividend Stock Paying 5.1% Monthly

Choice Properties could be a great monthly dividend stock for TFSA investors seeking attractive passive income and long-term growth potential.

Read more »